会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • HCV INHIBITIING SULFONAMIDES
    • HCV抑制磺酰胺
    • WO2005030194A1
    • 2005-04-07
    • PCT/EP2004/052388
    • 2004-09-30
    • TIBOTEC PHARMACEUTICALS LTD.SIMMEN, Kenneth AlanVAN ACKER, Koenraad Lodewijk AugustWIGERINCK, Piet Tom Bert PaulSURLERAUX, Dominique Louis Nestor GhislainDAMS, Géry Karel JuliaQUIRYNEN, Ludo Maria MarcelHERTOGS, KurtPAUWELS, Rudi Wilfried Jan
    • SIMMEN, Kenneth AlanVAN ACKER, Koenraad Lodewijk AugustWIGERINCK, Piet Tom Bert PaulSURLERAUX, Dominique Louis Nestor GhislainDAMS, Géry Karel JuliaQUIRYNEN, Ludo Maria MarcelHERTOGS, KurtPAUWELS, Rudi Wilfried Jan
    • A61K31/18
    • A61K45/06A61K31/18A61K31/421A61K31/426A61K2300/00
    • The present invention concerns sulfonamide derivatives having the general formula (I) and N -oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs and esters thereof, wherein Q 1 is -S- or -O-; R 1 is hydrogen, C 1-6 alkyl, hydroxy, amino, halogen, aminoC 1-4 alkyl and mono-or di(C 1-4 alkyl)amino; R 2 is hydrogen or C 1-6 alkyl; R 3 is C 1-6 alkyl, aryl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, or arylC 1-4 alkyl; R 4 is hydrogen, C 1-4 alkyloxycarbonyl, carboxyl, optionally mono- or disubstituted aminocarbonyl, mono- or di(C C 1-4 alkyl)aminocarbonyl, C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkyl optionally substituted with one or more substituents each independently selected from aryl, Het 1 , Het 2 , C 3-7 cycloalkyl, C 1-4 alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C 1-4 alkyl)aminocarbonyl, aminosulfonyl, C 1-4 alkylS(=O) t , hydroxy, cyano, halogen or amino optionally mono- or di-substituted where the substituents are each independently selected from C 1-4 alkyl, aryl, arylC 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, Het 1 , Het 2 Het 1 C 1-4 alkyl and Het 2 C 1-4 alkyl; Q 2 is a radical of formulae (III, IV, V, VI, VII) for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The present invention also relates to the use of said sulfonamides in pharmaceutical compositions aimed to treat or combat combined HCV and HIV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present sulfonamides with other anti-HCV agents and/or anti-HIV agents.
    • 本发明涉及具有通式(I)和N-氧化物,盐,立体异构形式,外消旋混合物,前药和酯的磺酰胺衍生物,其中Q1是-S-或-O-; R 1是氢,C 1-6烷基,羟基,氨基,卤素,氨基C 1-4烷基和单或二(C 1-4烷基)氨基; R2是氢或C1-6烷基; R 3是C 1-6烷基,芳基,C 3-7环烷基,C 3-7环烷基C 1-4烷基或芳基C 1-4烷基; R4是氢,C1-4烷氧基羰基,羧基,任选的单取代或二取代的氨基羰基,单或二(C 1 -C 1-4烷基)氨基羰基,C 3-7环烷基,C 2-6烯基,C 2-6炔基或任选被 一个或多个取代基,各自独立地选自芳基,Het 1,Het 2,C 3-7环烷基,C 1-4烷氧基羰基,羧基,氨基羰基,一或二(C 1-4烷基)氨基羰基,氨基磺酰基, 4-烷基S(= O)t,羟基,氰基,卤素或氨基,其中取代基各自独立地选自C 1-4烷基,芳基,芳基C 1-4烷基,C 3-7环烷基,C 3-7环烷基C 1-4烷基, Het 1,Het 2 Het 1 C 1-4烷基和Het 2 C 1-4烷基; Q2是制备用于抑制HCV感染的哺乳动物的HCV活性的药物的式(III,IV,V,VI,VII)的基团。 本发明还涉及所述磺酰胺在旨在治疗或对抗HCV和HIV感染综合症的药物组合物中的用途。 此外,本发明涉及这种药物组合物的制备方法。 本发明还涉及本发明磺酰胺与其它抗HCV剂和/或抗HIV剂的组合。